163 related articles for article (PubMed ID: 36655662)
21. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
[TBL] [Abstract][Full Text] [Related]
22. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
[TBL] [Abstract][Full Text] [Related]
23. High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Reismüller B; Steiner M; Pichler H; Dworzak M; Urban C; Meister B; Schmitt K; Pötschger U; König M; Mann G; Haas OA; Attarbaschi A;
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27804199
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
26. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
27. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
[TBL] [Abstract][Full Text] [Related]
28. [Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the
Zhang F; Lu AD; Zuo YX; Ding MM; Jia YP; Zhang LP
Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):543-549. PubMed ID: 35644195
[TBL] [Abstract][Full Text] [Related]
29. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia.
Ramos-Muntada M; Trincado JL; Blanco J; Bueno C; Rodríguez-Cortez VC; Bataller A; López-Millán B; Schwab C; Ortega M; Velasco P; Blanco ML; Nomdedeu J; Ramírez-Orellana M; Minguela A; Fuster JL; Cuatrecasas E; Camós M; Ballerini P; Escherich G; Boer J; DenBoer M; Hernández-Rivas JM; Calasanz MJ; Cazzaniga G; Harrison CJ; Menéndez P; Molina O
Mol Oncol; 2022 Aug; 16(16):2899-2919. PubMed ID: 35726693
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
31. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
32. [Interim results of a multicenter cohort study for Chinese Children Leukemia Group-acute lymphoblastic leukemia 2018 regimen].
Chinese Children Leukemia Group
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):874-880. PubMed ID: 37803853
[No Abstract] [Full Text] [Related]
33. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L; Liang Y; Pan J; Wang JR; Chai YH; Zhao WL
Pediatr Hematol Oncol; 2015 Apr; 32(3):173-81. PubMed ID: 25551271
[TBL] [Abstract][Full Text] [Related]
36. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
37. JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
Takahashi Y; Ishida H; Imamura T; Tamefusa K; Suenobu S; Usami I; Yumura-Yagi K; Hasegawa D; Nishimura S; Suzuki N; Hashii Y; Deguchi T; Moriya-Saito A; Kosaka Y; Kato K; Kobayashi R; Kawasaki H; Hori H; Sato A; Kudo T; Nakahata T; Oda M; Hara J; Horibe K
Int J Hematol; 2022 Jun; 115(6):890-897. PubMed ID: 35258855
[TBL] [Abstract][Full Text] [Related]
38. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
39. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
Maloney KW; Carroll WL; Carroll AJ; Devidas M; Borowitz MJ; Martin PL; Pullen J; Whitlock JA; Willman CL; Winick NJ; Camitta BM; Hunger SP
Blood; 2010 Aug; 116(7):1045-50. PubMed ID: 20442364
[TBL] [Abstract][Full Text] [Related]
40. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
